AMPH vs. RVMD, LNTH, BPMC, BBIO, LEGN, ELAN, CYTK, GRFS, NUVL, and VKTX
Should you be buying Amphastar Pharmaceuticals stock or one of its competitors? The main competitors of Amphastar Pharmaceuticals include Revolution Medicines (RVMD), Lantheus (LNTH), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Grifols (GRFS), Nuvalent (NUVL), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical products" industry.
Amphastar Pharmaceuticals vs.
Amphastar Pharmaceuticals (NASDAQ:AMPH) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, community ranking, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.
Amphastar Pharmaceuticals has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500.
65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are owned by insiders. Comparatively, 8.0% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Amphastar Pharmaceuticals received 301 more outperform votes than Revolution Medicines when rated by MarketBeat users. However, 75.83% of users gave Revolution Medicines an outperform vote while only 66.22% of users gave Amphastar Pharmaceuticals an outperform vote.
Amphastar Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Revolution Medicines had 2 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 6 mentions for Revolution Medicines and 4 mentions for Amphastar Pharmaceuticals. Revolution Medicines' average media sentiment score of 0.28 beat Amphastar Pharmaceuticals' score of -0.12 indicating that Revolution Medicines is being referred to more favorably in the news media.
Amphastar Pharmaceuticals presently has a consensus target price of $60.33, indicating a potential upside of 69.00%. Revolution Medicines has a consensus target price of $66.25, indicating a potential upside of 64.43%. Given Amphastar Pharmaceuticals' higher probable upside, research analysts clearly believe Amphastar Pharmaceuticals is more favorable than Revolution Medicines.
Amphastar Pharmaceuticals has a net margin of 21.80% compared to Revolution Medicines' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 26.44% beat Revolution Medicines' return on equity.
Summary
Amphastar Pharmaceuticals beats Revolution Medicines on 10 of the 19 factors compared between the two stocks.
Get Amphastar Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amphastar Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AMPH) was last updated on 1/18/2025 by MarketBeat.com Staff
